Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT00483925 |
| Other study ID # |
ES 511 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
June 6, 2007 |
| Last updated |
June 7, 2007 |
| Start date |
September 2005 |
Study information
| Verified date |
June 2007 |
| Source |
Laikon General District Hospital, Athens |
| Contact |
Gregory Kaltsas, MD, FRCP |
| Phone |
00302107462657 |
| Email |
gkaltsas[@]endo.gr |
| Is FDA regulated |
No |
| Health authority |
Greece: Ethics Committee |
| Study type |
Observational
|
Clinical Trial Summary
Langerhans-cell histiocytosis (LCH) is a rare disease with features of chronic inflammation
and hypopituitarism, conditions associated with increased risk of cardiovascular diseases.
Objective: To investigate glucose and lipid metabolism, insulin resistance, structural
arterial and functional endothelial properties in patients with multisystem LCH in a
prospective, observational study.
Interventions:Cardiovascular risk factors: arterial blood pressure, lipid profile,
mathematical indices of insulin resistance (IR), intima media thickness, brachial artery
flow mediated dilatation, dynamic indices of IR, pituitary function and C-reactive protein
will be estimated in patients with LCH and in a control group matched for gender, age, BMI
and smoking habits.
Description:
CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL
HISTIOCYTOSIS: EVIDENCE OF ABNORMALITIES OF CARBOHYDRATE METABOLISM
Langerhans cell histiocytosis (LCH) is a rare disease, usually affecting children although
it has recently increasingly been recognized in adults with a prevalence of approximately
1/560.000 cases ( , ). LCH is characterized by the aberrant proliferation of dendritic cells
of the monocyte-macrophage system that resemble normal epidermal Langerhans’ cells. These
cells can infiltrate many sites of the body leading to either localized lesions or
widespread systemic disease. Although LCH has been shown to be a clonal disorder ( ) it also
exhibits features of an inflammatory disease, as altered expression of cytokines and
cellular adhesion molecules important for the migration and homing of Langerhans cell has
been documented ( , ). In addition, LCH shows a particular predilection for
hypothalamo-pituitary axis (HPA) involvement leading to diabetes insipidus and/ or anterior
pituitary dysfunction in 15–50% and 5–20%, of patients respectively (3, , , ). These
percentages may be higher in adult patients with multisystem involvement, being 94% and 59%
respectively ( ).
The ongoing inflammatory process and the presence of hypopituitarism are considered to be
two independent risk factors for cardiovascular diseases probably through the induction of
insulin resistance (IR) ( , , ). The various therapies used for the treatment of multisystem
LCH, chemotherapy, radiotherapy and particularly glucocorticoids, may also adversely affect
the cardiovascular system mostly through IR ( , ). It is therefore possible that patients
with LCH represent a group at higher risk for cardiovascular diseases through the additive
effect of a number of different contributing mechanisms known to induce IR. Insulin
resistance besides producing an adverse metabolic profile can also lead to endothelial
dysfunction and early vascular disease ( ). Early vascular disease can be detected by
non-invasive surrogate markers, such as intima-media thickness (IMT) for vascular structure
properties and flow-mediated vasodilatation (FMD) for vascular functional properties ( , ,
). Carotid IMT is considered an established marker for early atherosclerotic disease and
predictor of future cardiovascular events (16) whereas brachial artery FMD has been
correlated with coronary endothelial function, a well-known predictor of future
cardiovascular events (18).
Main outcome measures: Cardiovascular risk factors assessment were estimated in patients
with LCH and compared to controls; the effect of hypopituitarism, disease activity and/ or
treatment were determined.
SUBJECTS AND METHODS All patients have to fulfil the diagnostic criteria for “definitive
diagnosis” of LCH ( ). Matched to sex, age, and BMI healthy individuals, in good health and
not receiving any medication known to affect carbohydrate, sex hormone metabolism, and/or
endothelial function for at least 3 months prior have also to be recruited for the study.
Clinical data of the patients as well as hormonal and imaging assessment will be registered.
All subjects do not have participate in strenuous physical activities and have to be on a
balanced isocaloric diet for at least 4 weeks prior to the study. Current smokers will be
asked not to smoke one day before the hemodynamic study.
Cardiovascular risk factors assessment:
Clinical cardiovascular risk:
- BMI
- waist circumference
- systolic (SBP) and diastolic (DBP) blood pressure Metabolic Profile
The metabolic study of all patients will be performed after a 10h overnight fasting:
- Oral glucose tolerance test
- Glucose, insulin
- Total cholesterol, HDL-cholesterol, triglycerides
- Indices of Insulin resistance [GIR ( ), HOMA ( ), QUICKI ( ), MATSUDA ( ), glucose and
insulin response to glucose by calculating the area under the curve (AUC) during the
OGTT performance for glucose (AUCGLU) and insulin (AUCINS), using the trapezoidal rule,
predicted index of first phase of insulin secretion, predicted index of second phase of
insulin secretion ( )].
Hemodynamic studies
- The hemodynamic study will be performed, the day after the metabolic study. Both
functional and structural arterial properties will be assessed by non-invasive, easily
reproducible hemodynamic ultrasonographic methods, namely: IMT measurement in carotid
arteries and both endothelium-dependent FMD and endothelium-independent nitrate-induced
dilatation (NID) measurement in brachial artery. IMT, FMD and NID were measured by
B-Mode high-resolution ultrasound imaging (VIVID PRO; GENERAL ELECTRIC) ( ).
- Arterial stiffness will be assessed by Applanation Tonometry (SphygmocorTM PWV MEDICAL)
on radial artery.
Inflammatory index C-reactive protein (CRP) measurement. References Baumgartner I, von
Hochstetter A, Baumert B, Luetolf U, Follath F 1997 Med Pediatr Oncol 28:9-14
- Dunger DB, Broadbent V, Yeoman E, Seckl JR, Lightman SL, Grant DB, Pritchard J 1989 The
frequency and natural history of diabetes insipidus in children with Langerhans-cell
histiocytosis N Engl J Med 321:1157-1162
- Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, Gilliland DG 1994
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease N Engl
J Med 331:154-160
- de Graaf JH, Tamminga RY, Dam-Meiring A, Kamps WA, Timens W 1996 The presence of
cytokines in Langerhans' cell histiocytosis J Pathol 180:400-40
- Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E 1999 Differential In situ
cytokine profiles of Langerhans-like cells and T cells in Langerhans cell
histiocytosis: abundant expression of cytokines relevant to disease and treatment Blood
94:4195-4201
- Malpas JS 1998 Langerhans cell histiocytosis in adults Hematol Oncol Clin North Am
12:259-26
- Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK 1996 Disease course and
late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University
of California, San Francisco J Clin Oncol 14:2073-2082
- Grois NG, Favara BE, Mostbeck GH, Prayer D 1998 Central nervous system disease in
Langerhans cell histiocytosis Hematol Oncol Clin North Am 12:287-305
- Makras P, Samara C, Antoniou M, Zetos A, Papadogias D, Nikolakopoulou Z, Andreakos E,
Toloumis G, Kontogeorgos G, Piaditis G, Kaltsas GA 2006 Evolving radiological features
of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis
(LCH) Neuroradiology 48:37-44
- Alexander RW 1994 Inflammation and coronary artery disease N Engl J Med. 1994 Aug
18;331(7):468-9
- Rosen T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in
hypopituitarism Lancet 336:285-288
- Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB 1999 Clustering of metabolic factors
and coronary heart disease Arch Intern Med 159:1104-1109
- Wei L, MacDonald TM, Walker BR 2004 Taking glucocorticoids by prescription is
associated with subsequent cardiovascular disease Ann Intern Med 141:764-770
- Andrews RC, Walker BR 1999 Glucocorticoids and insulin resistance: old hormones, new
targets. Clin Sci (Lond) 96:513-523
W Wheatcroft SB, Williams IL, Shah AM, Kearney MT 2003 Pathophysiological implications of
insulin resistance on vascular endothelial function Diabet Med 20:255-268
Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP 1998 The role of carotid
arterial intima-media thickness in predicting clinical coronary events.
Ann Intern Med 128:262-269
Schachinger V, Britten MB, Zeiher AM 2000 Prognostic impact of coronary vasodilator
dysfunction on adverse long-term outcome of coronary heart disease.
Circulation 101:1899-1906
Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P,
Creager MA, Yeung AC, et al 1995 Close relation of endothelial function in the human
coronary and peripheral circulations J Am Coll Cardiol 26:1235-1241
Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De
Juli E, Danesino C 2003 Langerhans cell histiocytosis in adults. Report from the
International Registry of the Histiocyte Society Eur J Cancer 39:2341-2348
Legro RS, Finegood D, Dunaif A 1998 A fasting glucose to insulin ratio is a useful measure
of insulin sensitivity in women with polycystic ovary syndrome J Clin Endocrinol Metab
83:2694-2698
Bergman RN, Prager R, Volund A, Olefsky JM 1987 Equivalence of the insulin sensitivity index
in man derived by the minimal model method and the euglycemic glucose clamp J Clin Invest
79:790-800
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ 2000 Quantitative
insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity
in humans J Clin Endocrinol Metab 85:2402-2410
Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance
testing. Comparison with the euglycemic insulin clamp Diabetes Care 22:1462-1470
Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich
J Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity
Diabetes Care 295–301
Alexandraki K, Protogerou A, Papaioannou TG, Piperi C, Mastorakos G, Lekakis J, Panidis D,
Diamanti-Kandarakis E 2006 Early Microvascular and Macrovascular Dysfunction is not
Accompanied by Structural Injury in Polycystic Ovary Syndrome. HORMONES (Athens Greece)
5:126-136
